High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allograft recipients according to American Diabetes Association criteria.
OBJECTIVE
The incidence of posttransplantation diabetes mellitus (PTDM) has been reported to vary according to different study populations or different definitions. In this study, using American Diabetes Association criteria, the incidence and clinical characteristics of PTDM in Korean renal allograft recipients undergoing tacrolimus-based immunosuppression were examined.


METHODS
A total of 21 patients taking tacrolimus as primary immunosuppressant were recruited and tested with a serial 75-g oral glucose tolerance test at 0, 1, 3, and 6 months after renal transplantation.


RESULTS
The cumulative incidence of PTDM was 52.4% at 1 month and 57.1% at 3 and 6 months. The baseline characteristics of the PTDM group were old age (especially >40 years), a high BMI, a high fasting glucose level, a high plasma insulin level, and increased insulin resistance. Among these parameters, old age was the only independent risk factor. The insulin secretory capacity in the PTDM group was maximally suppressed 3 months after transplantation. Thereafter, it was gradually restored along with dose reduction of tacrolimus.


CONCLUSIONS
Routine screening for PTDM is necessary in patients over 40 years of age who are undergoing a relatively higher dose tacrolimus therapy during the early course of postrenal transplantation.
Cho
Young Min
YM
Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Park
Kyong Soo
KS
Jung
Hye Seung
HS
Jeon
Hyun Jung
HJ
Ahn
Curie
C
Ha
Jongwon
J
Kim
Sang Joon
SJ
Rhee
Byoung Doo
BD
Kim
Seong Yeon
SY
Lee
Hong Kyu
HK
D000328:Adult; D002096:C-Peptide / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003920:Diabetes Mellitus / Q000139:chemically induced / Q000453:epidemiology*; D005260:Female; D005500:Follow-Up Studies; D005951:Glucose Tolerance Test; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000097:blood; D015994:Incidence; D007328:Insulin / Q000097:blood; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology; D012955:Societies, Medical; D016559:Tacrolimus / Q000009:adverse effects* / Q000097:blood; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D014481:United States
D002096:C-Peptide; D007166:Immunosuppressive Agents; D007328:Insulin; D014280:Triglycerides; D002784:Cholesterol; D016559:Tacrolimus